Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:791498.
doi: 10.1155/2015/791498. Epub 2015 Jan 18.

Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa)

Affiliations
Review

Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa)

Ademola Samson Adewoyin. Anemia. 2015.

Abstract

Sickle cell disease (SCD) predominates in sub-Saharan Africa, East Mediterranean areas, Middle East, and India. Nigeria, being the most populous black nation in the world, bears its greatest burden in sub-Saharan Africa. The last few decades have witnessed remarkable scientific progress in the understanding of the complex pathophysiology of the disease. Improved clinical insights have heralded development and establishment of disease modifying interventions such as chronic blood transfusions, hydroxyurea therapy, and haemopoietic stem cell transplantation. Coupled with parallel improvements in general supportive, symptomatic, and preventive measures, current evidence reveals remarkable appreciation in quality of life among affected individuals in developed nations. Currently, in Nigeria and other West African states, treatment and control of SCD are largely suboptimal. Improved knowledge regarding SCD phenotypes and its comprehensive care among Nigerian physicians will enhance quality of care for affected persons. This paper therefore provides a review on the aetiopathogenesis, clinical manifestations, and management of SCD in Nigeria, with a focus on its local patterns and peculiarities. Established treatment guidelines as appropriate in the Nigerian setting are proffered, as well as recommendations for improving care of affected persons.

PubMed Disclaimer

References

    1. Modell B., editor. Guidelines for the Control of Haemoglobin Disorders. Sardinia, Italy: WHO; 1989.
    1. Serjeant G. R. Sickle-cell disease. The Lancet. 1997;350(9079):725–730. doi: 10.1016/s0140-6736(97)07330-3. - DOI - PubMed
    1. Modell B., Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization. 2008;86(6):480–487. doi: 10.2471/blt.06.036673. - DOI - PMC - PubMed
    1. World Health Organisation 2008. Management of haemoglobin disorders. Proceedings of the Report of Joint WHO-TIF Meeting; November 2007; Nicosia, Cyprus.
    1. Piel F. B., Patil A. P., Howes R. E., et al. Global epidemiology of Sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. The Lancet. 2013;381(9861):142–151. doi: 10.1016/s0140-6736(12)61229-x. - DOI - PMC - PubMed

LinkOut - more resources